CUE BIOPHARMA INC (CUE)
US22978P1066 - Common Stock
Taking everything into account, CUE scores 2 out of 10 in our fundamental rating. CUE was compared to 588 industry peers in the Biotechnology industry. CUE may be in some trouble as it scores bad on both profitability and health. CUE is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
CUE had negative earnings in the past year.
In the past year CUE has reported a negative cash flow from operations.
CUE had negative earnings in each of the past 5 years.
In the past 5 years CUE always reported negative operating cash flow.
1.2 Ratios
CUE has a Return On Assets of -82.47%. This is in the lower half of the industry: CUE underperforms 71.92% of its industry peers.
CUE has a Return On Equity of -136.83%. This is in the lower half of the industry: CUE underperforms 62.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -82.47% | ||
| ROE | -136.83% | ||
| ROIC | N/A |
ROA(3y)-64.49%
ROA(5y)-57.94%
ROE(3y)-94.98%
ROE(5y)-81.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CUE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CUE has more shares outstanding
The number of shares outstanding for CUE has been increased compared to 5 years ago.
Compared to 1 year ago, CUE has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -7.20, we must say that CUE is in the distress zone and has some risk of bankruptcy.
CUE's Altman-Z score of -7.20 is on the low side compared to the rest of the industry. CUE is outperformed by 70.03% of its industry peers.
A Debt/Equity ratio of 0.11 indicates that CUE is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.11, CUE is not doing good in the industry: 64.55% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.2 |
ROIC/WACCN/A
WACC9.22%
2.3 Liquidity
A Current Ratio of 3.01 indicates that CUE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.01, CUE is doing worse than 66.10% of the companies in the same industry.
CUE has a Quick Ratio of 3.01. This indicates that CUE is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.01, CUE is not doing good in the industry: 64.73% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.01 | ||
| Quick Ratio | 3.01 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 26.00% over the past year.
CUE shows a strong growth in Revenue. In the last year, the Revenue has grown by 339.28%.
CUE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.94% yearly.
EPS 1Y (TTM)26%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q23.68%
Revenue 1Y (TTM)339.28%
Revenue growth 3Y20.34%
Revenue growth 5Y36.94%
Revenue growth Q2Q1114%
3.2 Future
The Earnings Per Share is expected to grow by 20.72% on average over the next years. This is a very strong growth
Based on estimates for the next years, CUE will show a very strong growth in Revenue. The Revenue will grow by 106.94% on average per year.
EPS Next Y-21.02%
EPS Next 2Y-29.04%
EPS Next 3Y-3.82%
EPS Next 5Y20.72%
Revenue Next Year-17.28%
Revenue Next 2Y-9.05%
Revenue Next 3Y92.9%
Revenue Next 5Y106.94%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CUE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CUE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as CUE's earnings are expected to decrease with -3.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.04%
EPS Next 3Y-3.82%
5. Dividend
5.1 Amount
CUE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CUE BIOPHARMA INC
NASDAQ:CUE (4/25/2024, 7:00:01 PM)
After market: 1.41 0 (0%)1.41
-0.01 (-0.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap68.58M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -82.47% | ||
| ROE | -136.83% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.01 | ||
| Quick Ratio | 3.01 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)26%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-21.02%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)339.28%
Revenue growth 3Y20.34%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y